



## DAFTAR PUSTAKA

- Aisner, J., 2007, Overview of the changing paradigm in cancer treatment: oral chemotherapy, *Am J Health Syst Pharm* 64, S4-7, <https://doi.org/10.2146/ajhp070035>.
- American Cancer Society, 2019, Treating Breast Cancer, <https://www.cancer.org/cancer/breast-cancer/treatment.html>.
- Baxter, K., Stockley, I.H. (Eds.), 2008, Stockley's drug interactions: a source book of interactions, their mechanisms, clinical importance, and management, 8th ed, *Pharmaceutical Press*, London.
- Becker, M.L., Kallewaard, M., Caspers, P.W.J., Visser, L.E., Leufkens, H.G.M., Stricker, B.H.C., 2007, Hospitalisations and emergency department visits due to drug-drug interactions: a literature review, *Pharmacoepidemiol Drug Saf* 16, 641–651.
- Binkhorst, L., van Gelder, T., Loos, W.J., de Jongh, F.E., Hamberg, P., Moghaddam-Helmantel, I.M.G., de Jonge, E., Jager, A., Seynaeve, C., van Schaik, R.H.N., Verweij, J., Mathijssen, R.H.J., 2012, Effects of CYP Induction by Rifampicin on Tamoxifen Exposure, *Clin Pharmacol Ther* 92, 62–67.
- Breast Cancer Network Australia, 2019, Types of breast cancer, <https://www.bcna.org.au/understanding-breast-cancer/what-is-breast-cancer/types-of-breast-cancer/>.
- Breitbart, W., 2011, Do antidepressants reduce the effectiveness of tamoxifen?, *Psycho-Oncology* 20, 1–4.
- Brickell, K., Porter, D., Thompson, P., 2003, Phenytoin toxicity due to fluoropyrimidines (5FU/capecitabine): three case reports, *Br J Cancer* 89, 615–616.
- Buajordet, I., Ebbesen, J., Erikssen, J., Brørs, O., Hilberg, T., 2001, Fatal adverse drug events: the paradox of drug treatment, *J. Intern. Med*, 250, 327–341.
- Campen, C.J., Vogel, W.H., Shah, P.J., 2017, Managing Drug Interactions in Cancer Therapy: A Guide for the Advanced Practitioner, *J Adv Pract Oncol* 8, 609–620.
- Carlini, P., Papaldo, P., Fabi, A., Felici, A., Ruggeri, E.M., Milella, M., Ciccarese, M., Nuzzo, C., Cognetti, F., Ferretti, G., 2006, Liver toxicity after treatment with gefitinib and anastrozole: drug-drug interactions through cytochrome p450?, *J. Clin. Oncol*, 24, e60-61.
- Centers for Disease Control and Prevention, 2019, What is Drug Interaction, <https://aidsinfo.nih.gov/understanding-hiv-aids/fact-sheets/21/95/what-is-a-drug-interaction>.
- Centers for Disease Control and Prevention, 2018, How is Breast Cancer Treated? [https://www.cdc.gov/cancer/breast/basic\\_info/treatment.html](https://www.cdc.gov/cancer/breast/basic_info/treatment.html).
- Centers for Disease Control and Prevention, 2018, What is Breast Cancer, [https://www.cdc.gov/cancer/breast/basic\\_info/what-is-breast-cancer.htm](https://www.cdc.gov/cancer/breast/basic_info/what-is-breast-cancer.htm).
- Chaieb, S.D., Chaumeil, J.-C., Jebnoun, S., Khrouf, N., Hedhili, A., Sfar, S., 2009, Effect of high calcium and phosphate concentrations on the physicochemical properties of two lipid emulsions used as total parenteral nutrition for neonates, *PDA J Pharm Sci Technol* 63, 27–41.
- Chalasani, P., 2020. Breast Cancer Medication, Medscape, <https://emedicine.medscape.com/article/1947145-medication>.
- Ciftci, R., Tas, F., Karabulut, S., Ciftci, S., 2015, Combination of capecitabine and phenytoin may cause phenytoin intoxication: a case report, *Am J Ther* 22, e17-19.
- Cope, D.G., 2013, Polypharmacy in older adults: the role of the advanced practitioner in oncology, *J Adv Pract Oncol* 4, 107–112.

- Copur, M.S., Ledakis, P., Bolton, M., Morse, A.K., Werner, T., Norvell, M., Muhvic, J., Chu, E., 2001, An adverse interaction between warfarin and capecitabine: a case report and review of the literature, *Annals of Oncology* 12, 1145–1150.
- Narrative review: Interaksi Obat pada Pasien Kanker Payudara**  
NISA AFIFA ADIYAR, D. Apt. Fita Rahmawati, Sp. FRS  
Universitas Gadjah Mada, 2020 | Diunduh dari <http://ed.repositori.ugm.ac.id/>
- Danesi, R., Innocenti, P., Fogli, S., Gennari, A., Baldini, E., Di Paolo, A., Salvadori, B., Bocci, G., Conte, P.F., Del Tacca, M., 2002, Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients, *Br J Clin Pharmacol* 53, 508–518.
- de Vos, A.I., Nooter, K., Verweij, J., Loos, W.J., Brouwer, E., de Bruijn, P., Ruijgrok, E.J., van der Burg, M.E.L., Stoter, G., Sparreboom, A., 1997, Differential modulation of cisplatin accumulation in leukocytes and tumor cell lines by the paclitaxel vehicle Cremophor EL, *Annals of Oncology* 8, 1145–1150.
- Dewi, G.A.T., Hendrati, L.Y., 2015, Analisis Risiko Kanker Payudara Berdasar Riwayat Pemakaian Kontrasepsi Hormonal dan Usia Menarche, *Jurnal Berkala Epidemiologi* 12–23.
- Dogliotti, L., Berruti, A., Buniva, T., Zola, P., Baù, M.G., Farris, A., Sarobba, M.G., Bottini, A., Alquati, P., Deltetto, F., Gosso, P., Monzeglio, C., Moro, G., Sussio, M., Perroni, D., 1996, Lomidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trial, *JCO* 14, 1165–1172.
- Drugs.com, 2019, Paclitaxel Drug Interactions, <https://www.drugs.com/drug-interactions/paclitaxel.html>.
- Fadilah, I.N., 2012, Evaluasi Drug Related Problems (Drps) Kategori Obat Salah, Dosis Rendah, Dosis Tinggi dan Interaksi Obat pada Pasien Kanker Payudara di Instalasi Rawat Inap RSUD “X” Tahun 2010.
- Faizah, A.K., 2018, Kajian Interaksi Obat pada Pasien Pneumonia di RS Pendidikan Surabaya, *SCIENTIA Jurnal Farmasi dan Kesehatan* 8, 86–91.
- Fogli, S., Danesi, R., Gennari, A., Donati, S., Conte, P.F., Del Tacca, M., 2002, Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer, *Annals of Oncology* 13, 919–927.
- Gianni, L., Munzone, E., Capri, G., Fulfarò, F., Tarenzi, E., Villani, F., Spreafico, C., Laffranchi, A., Caraceni, A., Martini, C., 1995, Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study, *J. Clin. Oncol.* 13, 2688–2699.
- Givens, C.B., Bullock, L.N., Franks, A.S., 2009, Safety of Concomitant Tamoxifen and Warfarin, *Ann Pharmacother* 43, 1867–1871.
- Gowarty, J.L., Herrington, J.D., 2019, Verapamil as a culprit of palbociclib toxicity, *J Oncol Pharm Pract* 25, 743–746.
- Gryn, S.E., Teft, W.A., Kim, R.B., 2014, Profound reduction in the tamoxifen active metabolite endoxifen in a patient on phenytoin for epilepsy compared with a CYP2D6 genotype matched cohort: Pharmacogenetics and Genomics 24, 367–369.
- Haidar, C., Jeha, S., 2011, Drug interactions in childhood cancer, *Lancet Oncol.* 12, 92–99.
- Hammann, F., Gotta, V., Conen, K., Medinger, M., Cesana, P., Rochlitz, C., Taegtmeier, A.B., 2017, Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity, *Br J Clin Pharmacol* 83, 927–930.
- Helms, R.A. (Ed.), 2006, Textbook of therapeutics: drug and disease management, 8th ed., Lippincott Williams & Wilkins, Philadelphia, Pa.
- Henry, N.L., Stearns, V., Flockhart, D.A., Hayes, D.F., Riba, M., 2008, Drug Interactions and Pharmacogenomics in the Treatment of Breast Cancer and Depression, *AJP* 165, 1251–1255.
- Hutson, P.R., Love, R.R., Havighurst, T.C., Rogers, E., Cleary, J.F., 2005, Effect of exemestane on tamoxifen pharmacokinetics in postmenopausal women treated for breast cancer, *Clin. Cancer Res.* 11, 8722–8727.
- Ingle, J.N., Suman, V.J., Johnson, P.A., Krook, J.E., Mailliard, J.A., Wheeler, R.H., Loprinzi, C.L., Perez, E.A., Jordan, V.C., Dowsett, M., 1999, Evaluation of tamoxifen plus letrozole

- with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer, *Clin. Cancer Res.* 5, 1642–1649.
- Narrative review: Interaksi Obat pada Pasien Kanker Payudara**
- Isaacs, K., Hains, N., 2005, Adverse Interaction Between Capecitabine and Warfarin Resulting in Altered Coagulation Parameters and Bleeding: Case Report and Review of the Literature, *Journal of Chemotherapy* 17, 339–342.
- Kamińska, M., Ciszewski, T., Łopacka-Szatan, K., Miotła, P., Starosławska, E., 2015. Breast cancer risk factors, *Prz Menopauzalny* 14, 196–202.
- Kelly, C.M., Juurlink, D.N., Gomes, T., Duong-Hua, M., Pritchard, K.I., Austin, P.C., Paszat, L.F., 2010, Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study, *BMJ* 340, c693–c693.
- Ko, Y., Tan, S.-L.D., Chan, A., Wong, Y.-P., Yong, W.-P., Ng, R.C.-H., Lim, S.-W., Salim, A., 2012, Prevalence of the coprescription of clinically important interacting drug combinations involving oral anticancer agents in Singapore: a retrospective database study, *Clin Ther* 34, 1696–1704.
- Loibl, S., Turner, N.C., Ro, J., Cristofanilli, M., Iwata, H., Im, S.-A., Masuda, N., Loi, S., André, F., Harbeck, N., Verma, S., Folkert, E., Puyana Theall, K., Hoffman, J., Zhang, K., Bartlett, C.H., Dowsett, M., 2017, Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results, *Oncologist* 22, 1028–1038.
- Lønning, P.E., Kvinnsland, S., Jahren, G., 1984, Aminoglutethimide and warfarin. A new important drug interaction. *Cancer Chemother, Pharmacol.* 12, 10–12.
- Lu, D., Li, C., Riggs, M., Polhamus, D., French, J., Agarwal, P., Chen, S.-C., Vadhavkar, S., Patre, M., Strasak, A., Quartino, A., Jin, J.Y., Girish, S., 2019, Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer, *Cancer Chemother Pharmacol* 84, 175–185.
- Micromedex, 2013. Drug Interaction.
- Montes, A., Powles, T.J., O'Brien, M.E.R., Ashley, S.E., Luckit, J., Treleaven, J., 1993, A toxic interaction between mitomycin C and tamoxifen causing the haemolytic uraemic syndrome, *European Journal of Cancer* 29, 1854–1857.
- Mouzon, A., Kerger, J., D'Hondt, L., Spinewine, A., 2013, Potential interactions with anticancer agents: a cross-sectional study, *Chemotherapy* 59, 85–92.
- Murray, L.S., Jodrell, D.I., Morrison, J.G., Cook, A., Kerr, D.J., Whiting, B., Kaye, S.B., Cassidy, J., 1998, The effect of cimetidine on the pharmacokinetics of epirubicin in patients with advanced breast cancer: preliminary evidence of a potentially common drug interaction, *Clin Oncol (R Coll Radiol)* 10, 35–38.
- National Breast and Ovarian Cancer Centre, 2009, Breast cancer risk factors: a review of the evidence.
- National Cancer Institute, 2019, NCI Dictionary of Cancer Terms, <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/chemotherapy>.
- National Cancer Institute, 2018, Cancer classification, <https://training.seer.cancer.gov/disease/categories/classification.html>.
- Planton, J., Edlund, B.J., 2010, Strategies for reducing polypharmacy in older adults, *J Gerontol Nurs* 36, 8–12.
- Popa, M.A., Wallace, K.J., Brunello, A., Extermann, M., Balducci, L., 2014, Potential drug interactions and chemotoxicity in older patients with cancer receiving chemotherapy, *J Geriatr Oncol* 5, 307–314.
- Privitera, M., de los Ríos la Rosa, F., 2011, Capecitabine–phenytoin interaction is dose dependent with an unexpected time course: Anti-Cancer Drugs 1.
- Reid, A.D., Horobin, J.M., Newman, E.L., Preece, P.E., 1992, Tamoxifen metabolism is altered by simultaneous administration of medroxyprogesterone acetate in breast cancer patients, *Breast Cancer Res Tr* 22, 153–156.

- Riechelmann, R.P., Tannock, I.F., Wang, L., Saad, E.D., Taback, N.A., Krzyzanowska, M.K., 2007, Potential drug interactions and duplicate prescriptions among cancer patients, *J. Natl. Cancer Inst.* 99, 1007–1014.
- Narrative review: Interaksi Obat pada Pasien Kanker Payudara**  
NISA AFIFA ADIYAR, Dy. apt. Fita Rahmawati, Sp. FRS  
Universitas Gadjah Mada, 2020. Diunduh dari <http://etd.repository.ugm.ac.id/>
- Scott, A., Scott, G.N.S., 2013, Mechanisms of Drug Interactions, *Pharmacy Tech Topics Volume 18*, No. 3.
- Scripture, C.D., Figg, W.D., 2006, Drug interactions in cancer therapy, *Nat. Rev. Cancer* 6, 546–558.
- Sharma, G.N., Dave, R., Sanadya, J., Sharma, P., Sharma, K.K., 2010, Various types and management of breast cancer: an overview, *J Adv Pharm Technol Res* 1, 109–126.
- Solberg, L.I., Hurley, J.S., Roberts, M.H., Nelson, W.W., Frost, F.J., Crain, A.L., Gunter, M.J., Young, L.R., 2004, Measuring patient safety in ambulatory care: potential for identifying medical group drug-drug interaction rates using claims data, *Am J Manag Care* 10, 753–759.
- Stearns, V., 2003, Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine, *CancerSpectrum Knowledge Environment* 95, 1758–1764.
- Tatro, D.S., 1996, Drug interaction facts. Facts and Comparisons, St. Louis, Mo.
- Tenni, P., Lalich, D.L., Byrne, M.J., 1989, Life threatening interaction between tamoxifen and warfarin, *BMJ* 298, 93.
- Teo, Y.L., Saetaew, M., Chanthawong, S., Yap, Y.S., Chan, E.C.Y., Ho, H.K., Chan, A., 2012, Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence, *Breast Cancer Res Treat* 133, 703–711.
- Trissel, L.A., Gilbert, D.L., Martinez, J.F., 1997, Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration, *Am J Health Syst Pharm* 54, 1287–1292.
- Tsifi, A., Papaxoinis, G., Diamantopoulos, P., Mantzourani, M., Antoniadou, V., Halioti, A., Gogas, H., 2019, A life-threatening drug-drug interaction between capecitabine and brivudine in a patient with metastatic breast cancer, *Journal of Chemotherapy* 31, 424–427.
- Tyler, T., 2011, Drug interactions in metastatic breast cancer, *J Oncol Pharm Pract* 17, 236–245.
- Ussai, S., Petelin, R., Giordano, A., Malinconico, M., Cirillo, D., Pentimalli, F., 2015, A pilot study on the impact of known drug-drug interactions in cancer patients, *J Exp Clin Cancer Res* 34, 89.
- van Leeuwen, R.W.F., Swart, E.L., Boven, E., Boom, F.A., Schuitenmaker, M.G., Hugtenburg, J.G., 2011, Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method, *Ann. Oncol.* 22, 2334–2341.
- Wang, W., Xiao, B., Liu, Z., Wang, D., Zhu, M., 2019, The Prevalence of the Potential Drug-Drug Interactions Involving Anticancer Drugs in China: A Retrospective Study.
- Wang, X., Song, Y., Wang, J., He, J., Liu, R., Li, X., Huang, H., Zhang, J., 2020, Effect of proton pump inhibitors on high-dose methotrexate elimination: a systematic review and meta-analysis, *Int J Clin Pharm* 42, 23–30.
- Webb, D.J., Freestone, S., Allen, M.J., Muirhead, G.J., 1999, Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist, *Am. J. Cardiol.* 83, 21C–28C.
- World Health Organization, 2018, Cancer, <https://www.who.int/en/news-room/fact-sheets/detail/cancer>.